Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Lola McEvoy is set to press the government upon the use of Enhertu after the death of Heather Sawyer - a Darlington grandmother who campaigned for the drug she believed would have extended her life.

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average. The health assessment body, NICE, is the only organisation ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's National Medical Products Administration (NMPA) as a single agent for adult patients with a specific type of non ...

ENHERTU is indicated for patients with unresectable or metastatic NSCLC with activating HER2 mutations who have previously undergone systemic therapy. Credit: Nemes Laszlo/Shutterstock. Daiichi Sankyo ...

UK pharma major AstraZeneca (LSE: AZN) and Japanese drugmaker Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab deruxtecan) has won conditional approval in China as a monotherapy for the treatment of ...

The FDA approved the first treatment for MASH in March this year. Image credit: Shutterstock/ Iurii Motov. Inventiva has secured up to €348m ($380m) in financing to help wrap up a Phase III trial for ...

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors and ADCs. Enhertu ...

The results for Enhertu in HER2-low breast cancer were released at the plenary session of the American Society of Clinical Oncology and delivered "data fit for a queen", analysts Luisa Hector ...

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer. If approved the new indication for ...